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Summary
To study the effects oflocalized secretion ofcytokines on tumor progression, the gene for human
interleukin 2 (IL2) was introduced via retroviral vectors intoCMS-5 cells, a weakly immunogenic
mouse fibrosarcoma cell line of BALB/c origin. Secretion of low levels of 11,2 from the tumor
cells abrogated their tumorigenicity and induced a long-lasting protectiveimmune response against
a challenge with a tumorigenic dose of parental CMS-5 cells. Co-injection of IL2-producing
CMS-5 cells with unmodified tumor cells inhibited tumor formation evenwhen highly tumorigenic
doses of CMS-5 cells were used . Cytolytic activity in mice injected with parental CMS-5 cells
was transient and was greatly diminished 3 wk after injection, as commonly observed in tumor-
bearing animals. However, in mice injected with IL-2-producing cells, tumor-specific cytolytic
activity persisted at high levels for the duration of the observation period (at least 75 d) . High
levels oftumor-specific cytolytic activity could also be detected in parental CMS-5 tumor-bearing
animals 18 d after inoculation with tumor cells, if 11,2-producing CMS-5 cells but not unmodified
parental tumor cells were used as targets . These studies highlight the potential advantages of
localized secretion of cytokines mediated via gene transfer to induce potent anti-tumor immune
responses.
C
hemically induced tumors in animals possess tumor-
specific antigens (TSA), 1 as demonstrated by the ability
of animals transplanted with a syngeneic tumor to reject a
second challenge of the same tumor (1-3) . The relevance of
these observations to human neoplasia has been questioned,
since spontaneously arising tumors in mice are essentially
nonimmunogenic, suggesting that the existence of highly
immunogenic tumors in nature is quite rare (4) . While it
now appears that at least some spontaneous tumors can be
recognized by the immune system, even these elicit a weak
immune response of little or no protective value (5) . In sev-
eral instances, however, weak anti-tumor responses generated
in animals bearing "nonimmunogenic" tumors could be poten-
tiated, protecting the animal from a subsequent tumor chal-
lenge (5-7) . The growth of some tumors in experimental
animals, as well as in human patients, is often associated with
the establishment of an active state ofimmune suppression
(8-10) . Studies by North and co-workers using chemically
induced tumors in mice similar to the tumor system used
in our studies, have shown that tumor progression in the
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animal induced a population of Lyt-1+2 - T cells that sup-
pressed the emerging anti-tumor response mediated by Lyt-
1 - 2+ T cells (10) .
IL-2 is a growth factor that stimulates the proliferation of
cytotoxic T cells (11), helper T cells (12), NK cells (13), and
LAK cells (14), all of which can participate in the anti-tumor
response. In the mouse, systemic administration of IL-2 in-
duces the expansion and long-term persistence of adoptively
transferred tumor-specific T cells (15-18) . To test whether
"locally" secreted cytokines were able to influence the gener-
ation of anti-tumor immune responses we used retroviral
vectors to introduce the gene for human IL-2 into CMS-5
cells. CMS-5, a methylcholanthrene-induced tumor inBALB/c
mice, is a weakly immunogenic tumor devoid of viral an-
tigens (19, 20) . The effect of varying levels of cytokine ex-
pression on tumor growth in vivo and on the generation of
a cellular immune response was then measured .
Our results demonstrated that local secretion of IL-2
abrogated the tumorigenicity of the cytokine-producing CMS-
5 cells and induced a long-lasting protective immune response
against a subsequent tumor graft . The IL-2-producing tumor
cells abrogated growth of co-injected tumor cells that were
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state ofT cell immunity as measured by persistence ofa specific
cytotoxic activity. These results suggest that modification of
tumor cellswith cytokine genes is a potentially useful strategy
to manipulate thehost mediated anti-tumor immune response .
Materials and Methods
Retroviral Vector Design and Infection of Tumor Cells.
￿
A 528-bp
longDNA fragment encoding thehumanIL2cDNA was obtained
from the plasmid PBCII/RSV/AT (21) by digestion with restric-
tion enzymes BamHI andHindIIl . A852-by-longDNAfragment
encoding theHSV thymidine kinase (TK) promoter was obtained
from plasmidPHSV106 (22) by digestion with restriction enzymes
BamHI and BglII . A 794-by-long DNA fragment encoding the
majorimmediate earlyhumanCMVpromoter was obtained from
plasmid PRR23 (23) by digestion with restriction enzymes Ball
and SmaI . N2 is a retroviral vector derived from the genome of
Moloney murine leukemia virus (MLV), containing the bacterial
neomycin resistance (neo)gene which is used as a selectable marker
(24) . A schematic diagram presenting the various vector constructs
used in these studies is shown in Fig . 1 . Vector N2/1L2 was con-
structed by cloning the IL-2 cDNA into a unique Bc1I site present
upstream from the initiation codon of the neo gene generating a
bicistronic transcriptional unit . TheTK andCMV promoter en-
coding DNA fragments were fused to the IL2 cDNA fragments
andcloned into aunique Xhol site present downstream to the neo
gene coding sequences to generate vector constructs N2/TKIL2
and N2/CMVIL2. The TKIL2 fusion product was cloned into
theSnaBI site present in the polylinker in the 3'LTR ofa modified
N2 vector as described by Hantzopoulos et al . (25), to generate
vector constructs DC/TKIL2 . The prefixDC is short forDouble
Copy to describe this vector design in which the foreign gene is
inserted into the 3' LTR of retroviral vector. For more details on
DC vectors, seeHantzopoulos et al . (25) .DCA is a previously de-
scribed vector in which thehumanADAminigene wascloned into
the 3'LTRoftheN2 vector (25) . Retroviral vector constructs were
converted to corresponding virus using established procedures.
Briefly, vector DNA was transfected into a helper-free, ecotropic
(N2/IL2, N2/TKIL2, N2/CMVIL2, and DC/TKIL2) or am-
photropic (DCA) packaging cell line (26, 27) . Colonies were iso-
latedby G418 selection, expanded to cell lines, and cell-free super-
natant was tested for the presence ofvirus. Cell lines secreting high
titer of virus (106-105/Neo CFU/ml) were used to infect CMS-5
cells. Clonal derivates ofCMS-5 cells were isolated by G418 selec-
tion, expanded to cell lines, and secretion of IL2 into the cell su-
pernatant was measured . Absence of replication-competent virus
in the cytokine-producing CMS-5 cellswas shownby the inability
to transfer G418 resistance to NIH 3T3 cells .
Human 11,2 Assay.
￿
Supernatant from 2 x 106 semiconfluent
unmodified or 11,2 secreting CMS-5 cells was collected after 48 h
and assayed for human IL-2 . IL2 activity was measured using
IL2-dependenthuman primary lymphoblasts in a proliferation assay
as previously described (28), and results were confirmedby ELISA
(Genzyme, Boston, MA). DMS-1, a specific mAb to human 11,2
(29), was used to inhibit IL2 activity.
Tumor Cell Lines andAnimal Studies.
￿
CMS-5 is a methylcho-
lanthrene-induced fibrosarcoma of BALB/c origin, shown to be
devoid of viral antigens (19) and weakly immunogenicwhen com-
pared with CMS-13 or Meth A, two noncrossreacting methyl-
cholanthrene-induced tumors of the same genetic background
(Srivastava, P., personal communication; reference 20) . CMS-5,
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CMS-13,andMethA were adapted to culture andgrown inDMEM
medium supplemented with10% FCS.BALB/c mice were obtained
from a colony bred at Sloan-Kettering Institute, from whichCMS-5,
CMS-13, andMethAtumors originated . Tumor cell injections were
carried out using freshly prepared tumor cells that were removed
from theculture plates by trypsinization andwashed twice in PBS.
Cells were injected intradermally in the dorsal root of the animal.
Tumor growth was measured in millimeters using a caliper and
wasrecorded as mean diameter (longest surface length (a) andwidth
(b), (a + b):2) .
"Cr-release Assay.
￿
Cytotoxicity of spleen cells from tumor-
bearingandtumor-free BALB/c mice was assayedon different target
cells in an 18-h "Cr-release assayand carried out in U-bottomed,
96-well microtiter plates . CTLwere generated by culturing in vivo
immunized spleen cells for 6 d at a concentration of 106 cells/ml
inRPMI medium, 10% FCS, penicillin, streptomycin, and 2mM
L-glutamine, together with 2.5 x 104 irradiated (6,000 rad) CMS-5
stimulator cells/ml. Cultures were harvestedon day6 . Target cells
were prepared by culturing cells for 1 h in the presence of 250ACi
of "Crsodium chromate, washed twice, and counted . 10 4 labeled
target cells per well were mixed with effector lymphocytes to yield
severalE/T cell ratios andwere incubated for 18 h . Percent specific
lysis was calculated as : 100 x [(cpm experimental wells - cpm .
spontaneous release)/(cpm maximum release - cpm spontaneous
release)]. Spontaneous release of all targets was <25% .
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Figure 1 .
￿
Structure of retroviral vectors containing the human IL2
cDNAs (For additional details see Materials and Methods) .Results
Generation ofTumor Cell LinesExpressingIL2.
￿
Fig. 1 shows
the retroviral vector constructs that were used to introduce
and express the human IL -2 gene in tumor cells. The retroviral
vectors used in this study were derived from MLV and are
based on the high titer N2 retroviral vector, which also con-
tains the bacterial neomycin resistance (neo) selectable gene
(24) . For additional details see Materials and Methods. Vector
DNA was converted to corresponding virus using established
procedures . Briefly, vectorDNA was transfected into a pack-
aging cell line, and neomycin resistant colonies were selected
with G418 . Drug-resistant colonies were isolated and expanded
to cell lines. Virus-containing cell-free supernatant was used
to infect CMS-5 cells and clones were isolated. DNA blot
analysis of G418-resistant CMS-5 cellswas used to show that
an intact provirus was present in the infected cells (data not
shown) .
Expression of the IL2 gene in the CMS-5 cells transduced
with the retroviral vectors was determined by measuring the
secretion of the cytokine into the cell supernatant first using
a bioassay and then confirming these results with an ELISA
test (Table 1) . Clonal isolates of CMS-5 cells were found to
vary in their expression and secretion of IL2 depending on
the particular retroviral vector used (Table 1) . In each case,
human IL2 activity could be neutralized by an appropriate
mAb (data not shown). Secretion ofhuman IL2 had no dis-
cernible effect on cell morphology or on the growth rate in
culture compared with parental CMS-5 cells or CMS-5 cells
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Used in subsequent experiments.
transduced with the control DCA vector (data not shown) .
These results underscored the importance of retroviral vector
design and of the choice of expression system in these kinds
of studies. Furthermore, they provided an opportunity to test
the effects ofvarying levels ofcytokine production on tumori-
genesis.
The Effect ofIL2 Secretion on Tumor Growth In Viva
￿
The
main question addressed in this study was whether the local
secretion of IL2 from the genetically modified cells would
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Figure 2 .
￿
Growth of parental and
cytokine producing CMS-5 cells in
BALB/c mice. Groups of five mice in
each category were injectedwith 2.5 x
105 tumor cells as indicated . Tumor
growth was monitored as described in
Materials and Methods .
Table 1 . IL-2 Secretion from Vector-transduced CMS-5 Cells
IL-2/CMS-5 Clones
Vector construct 1' 2 3 4
IL-2 U/ml
N2/IL2/CMS5 30 29 25 23
N2/CMVIL2/CMS5 15 12 6 5
DC/TKIL2/CMS5 19 15 15 15
N2/TKIL2/CMS5 1 0.5 0.5 0.5
DCA/CMS5 0 0 0 0
CMS-5 0 0 0 0affect their tumorigenicity in vivo . This was tested in two
ways. First, equal numbers ofunmodified or vector-modified
CMS-5 cells were injected intradermally (i.d .) into the back
of syngeneic BALB/c mice and the appearance and size of
the resulting tumor were monitored over time . The results
of the representative experiment shown indicated that mice
injected with either 2.5 x 105 unmodified CMS-5 cells (Fig .
2A) or with cells harboring the irrelevant vectorDCA, which
expresses the human ADA gene product (Fig . 2 B), devel-
oped tumors at the site of injection and had to be killed by
day 40 . On the other hand, in mice injected with various
IL-2-producing CMS-5 cells, tumor growth correlated in-
versely with the amount of IL-2 secreted by the tumor cells.
No tumors were induced in mice injected with high IL2-
producing cells (N2/IL2/CMS5, Fig. 2 F) . In mice that re-
ceived CMS-5 cells that secreted intermediate levels of IL2,
tumor growth was significantly retarded and mice survived
for over 75 d (N2/CMVIL2/CMS5, DC/TKIL2/CMS5 Fig.
2, D and E, respectively) . Tumor growth was minimally
affected in mice injected with low IL2-producing cells (N2/
TKIL2/CMS5, Fig. 2 C) .
The second approach used to measure the effect of cytokine
production on tumorigenicity involved evaluating the numbers
of IL-2-secreting tumor cells that could be injected without
causing tumors. Whereas injection of only 10 5 CMS-5 cells
into BALB/c mice caused the appearance of large tumors in
five of six animals, injection of as many as 106 IL-2 pro-
ducing CMS-5 cells (N2/IL2/CMS5) failed to result in tumors
(Table 2) . Thus, localized IL2 secretion altered the ability
of CMS-5 cells to cause tumors in vivo .
In Vivo Immune Response Generated by Cytokineproducing
CMS-5 Cells. An association between cytokine secretion and
growth of modified tumor cells, such as we observed, could
be a result of altered growth properties of the tumor cells
following the genetic manipulation they underwent or ofan
immune response triggered by the cytokines . We excluded
the first possibility, since our results showed no change on
cell morphology, viability, or growth rate in culture ofvector
modified tumor cells compared with parental CMS-5 cells
(data not shown) . To test the more intriguing possibility that
increased amounts of cytokine secretion played a role in the
reduced outgrowth of tumor cells an experiment was per-
formed in which 106 N2/IL2/CMS5 cells were mixed with
increasing numbers of unmodified tumor cells and injected
into mice. Our results indicated that co-injection of 106 1172-
producing cells was able to induce the rejection of up to
8 x 10 5 unmodified tumor cells (Fig . 3) . Although 1.6
x 106 tumor cells were not rejected, the growth of the
resulting tumor was considerably reduced . In fact, injection
of 2 x 105 unmodified tumor cells alone generated a larger
tumor than injection of 1.6 x 106 tumor cells mixed with
the IL2-producing cells . These observations demonstrated
that local secretion of IL2 influenced the growth ofunmodified
tumor cells and were consistent with the hypothesis that an
immune response was induced that was responsible for the
loss of tumorigenicity of CMS-5 cells .
Further support for this hypothesis was obtained when
mice that had rejected an 1172-producing CMS-5 tumor were
Table 2 .
￿
Tumorigenic Potential of Parental and Cytokine-
producing CMS-5 Cells
E
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" Growing slowly and regressing after several weeks .
challenged after 6 wk with 2 x 105 CMS-5 cells, a number
that usually causes tumor formation . All mice failed to show
tumors at the site of the challenge (Table 3) . Furthermore,
Meth A and CMS-13, two noncrossreactive methylcholan-
CM56200K
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Figure 3 .
￿
In vivo growth inhibition ofparental CMS-5 cells mixed with
IL-2-producing CMS-5 cells . 106 IL-2-producing CMS-5 cells,
N2/IL2/CMS5 1M, were mixedwith increasing numbers ofparental CMS-
5 cells as indicated, injected into the back of BALB/c mice and tumor
growth monitored . Three mice were used in each group and the mean
diameter for each group was used in the calculations .
Tumor
Injection dose
(Number of cells)
Number of mice
with tumor per
number mice
injected
Parental CMS-5 50,000 0/3
100,000 5/6
150,000 8/9
200,000 15/15
250,000 15/15
N2/IL-2/CMS-5 125,000 0/3
250,000 0/8
500,000 0/3
1,000,000 0/19
2,000,000 2/2'Table 3 .
￿
Challenge of Mice that Rejected Cytokine-producing
Tumor Cells with Parental CMS-5 Cells
Number of mice with
tumor' per number
Rejected tumor
￿
of mice injected
DC/TKIL2/CMS5
￿
0/3
N2/IL2/CMS5
￿
0/3
Controlt
￿
5/5
BALB/c mice were challenged with 2 x 105 CMS-5 cells in the left
flank 6 wk after injection of 2.5 x 105 cytokine-producing tumor cells .
t Unimmunized BALB/c mice of the same age group .
trene-induced fibrosarcomas of the same genetic background,
were not rejected (data not shown) . Both of these cell lines
had beengrown in vitro in a fashion identical toCMS-5 cells,
thereby also eliminating the possibility that rejection ofCMS-5
cells was due to sensitization to serum proteins. Since all control
mice developed tumors, protection was specific. Thus, the
abrogation oftumorigenicity was characterized by a process
that wasCMS-5 specific, had memory, and was best explained
by the existence ofa protectiveimmune response against the
parental tumor.
In Vitro Lytic Activity ofSpleen Cells Derivedfrom Animals
Injected with Parentaland Cytokineproducing CMS-5 Cells. Next
we tested whether aCTL response might be at least partially
responsible for the failure of IIr2-producing tumor cells to
grow . Sincewe reasoned that an ongoing anti-tumorimmune
response would best be detectable in animals exhibiting re-
duced tumor growth, spleens were taken from mice that had
been inoculated with IL2-producing tumor cells that grew
at a significantly reduced rate, or from mice injected with
unmodified CMS-5 cells. The nonadherent T cell-enriched
populations were then cocultured in vitro with irradiated,
parental CMS-5 cells for 6 d and tested in a standard "Cr-
release assay for their ability to lyse various targets including
parental CMS-5 cells, an IL2-producing CMS-5 line
(N2/IL2/CMS5), K562, an NK-sensitive cell line, andCMS-
13, a methylcholanthrene induced noncrossreactive BALB/c
fibrosarcoma (20) .
Our results indicated that mice injected with unmodified
CMS-5 cells were able to lyse parental CMS-5 cells and IL-
2-producing CMS-5 cells, if effector spleen cells were taken
at day 11 after injection oftumor cells (Fig. 4, upper left) .
Neither K562 nor CMS13 cells were lysed . In other experi-
ments, YAC-1 cells, another NK sensitive cell line, were also
shown to be resistant to lysis by the activated spleen cells
(data not shown) . On the other hand, if spleen cells were
taken from mice inoculated with the unmodified tumor 28 d
after the injection of CMS-5 cells, there was no longer de-
tectable lysis ofunmodified CMS-5 cells (Fig. 4, upper right) .
This observation is consistent with the transient nature of
the CTL response against CMS-5 and several other mouse
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￿
In vitro lytic activity in the spleens of animals injected with
parental and cytokine-producing CMS-5 cells. BALB/c mice were injected
with 2 .5 x 105 tumor cells, spleens were isolated at specified time (see
below), stimulated in vitro with irradiated parental CMS-5 cells and used
as effectors in a 5'Cr-release assay against various targets shown in the
legend ofCMS5d11 in the upper left (see Materials and Methods for addi-
tional details) . Mice were injected with : CMS5d11, unmodified CMS-5
cells, spleens isolated 11 d later; CMS5d28, unmodified CMS-5 cells, spleens
isolated 28 d later; N2/CMVIL2/CMS5d75, N2/CMVIL2/CMS5 cells,
spleens isolated 75 days later; DC/TKIL2/CMS5d75, DC/TKIL2/CMS5
cells, spleens isolated 75 d later.
tumors, which is followed by the emergence ofa state of im-
mune suppression mediated by a population oftumor-specific
T suppressor cells (10, 30, 31) . In contrast, spleen cells de-
rived as late as 75 d after injection of IL2-producing CMS-5
cells still demonstrated a strong CTL response, similar to that
observed with spleen cells taken 11 d after injection of un-
modified CMS-5 cells (Fig. 4, lower left and lower right) . Thus,
the normal transient CTL response was not seen in the mice
injected with IL-2-secreting tumors, but rather was replaced
by one that was long lived .
We attempted to investigate in vitro whether secretion of
IL-2 by the tumor cells could influence T cell activity by testing
the ability of parental CMS-5 cells and their IL-2-producing
counterparts to serve as targets for CTL . Effector cells were
produced by inoculating mice with parental CMS-5 cells. After
18 d spleen cells were isolated, stimulated in vitro for 6 d
with irradiated unmodified CMS-5 cells, and used as effectors
in a CML assay against a panel of targets . As expected, given
theimmune suppression in mice inoculated with tumor cells
close to 3 wk before the harvest of spleen cells (10), only
low levels of lysis was observed when unmodified CMS-5
cells were used as targets (Fig . 5) . In contrast, efficient lysis
was observed when 11,2-producing CMS-5 cells were used
as targets (Figs . 4 and 5) . Moreover, the efficiency of lysis50 ,
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Figure 5 . Cell-mediated lympholysis against different IL-2-secreting
target cells . Mice were injected with 2.5 x 105 CMS-5 cells, spleens were
isolated 18 d later, cultured in vitro for 6 d in the presence of irradiated
CMS-5 cells, and used in a SICr-release assay against targets, as indicated .
of various targets was directly proportional to the level of
11,2 secreted by the target cells. (N2/IL2/CMS5 >
N2/CMVIL2/CMS5 > N2/TKIL2/CMS5, see Table 1) .
Even parental CMS-5 cells could bemade susceptible to lysis
by the addition of exogenous 11,2 during the 18 h of incuba-
tion with the activated CTL . It is estimated that 1-3 U/ml
of IL2 accumulate during the lysis reaction when 10,000
N2/IL2 vector-containing CMS-5 cells are used as targets,
while 30 U/ml of exogenous IL2 were used in the experi-
mentshown in Fig . 5 . In other experiments (data not shown),
5 and 2 U/ml of exogenous IL2 were effective at inducing
lysis of CMS-5 cells, indicating that IL2 secretion from the
tumor cells could indeed be responsible for the increase in
lysis seen . Additional support was obtained in experiments
in which the addition of an anti-IL2, but not control, mAb
to the overnight CML reaction inhibited the lysis of N2/IL-
2/CMS-5 target cells by -50% (data not shown) . The pos-
sibility that the secreted 11,2 was responsible for the increased
target cell destruction by reducing the viability of the target
cells during the 18-h incubation period was excluded, since
there was no lysis by lymphocytes that were taken directly
from parental CMS-5 tumor-bearing mice and exposed to
IL-2-secreting target cells without a 6-d period of cocultiva-
tion (data not shown) .
Systemic administration of cytokines into experimental
animals is used with increased frequency to probe the func-
tions of theimmune system and to enhance the immunother-
apeuticvalue oftreatments for viral diseases and cancer. Transfer
of cytokine genes into tumor cells approximates more closely
the physiological mode of cytokine secretion in the course
of an immune response, because it leads to the highly local-
ized secretion of low levels of cytokines which ceases with
the regression of the tumor. Retroviral gene transfer is a highly
efficient method to introduce genes into mammalian cells,
resulting in integration of cytokine genes into the cell chro-
mosome and persistent expression of low levels of cytokine.
In this study retroviral vectors were used to introduce and
express the 11,2 gene in CMS-5 cells (Table 1) .
Though we estimated that <50-400U of IL2 were secreted
from the tumor cells injected in the back of the mouse (as-
suming that the injected tumor cells increase in number -10-
fold and persist in the mouse for 1 wk before complete regres-
sion), our results demonstrated that the modification ofweakly
immunogenic tumor cells to secrete 11,2 effectively abrogated
their ability to form tumors in mice (Fig . 2 and Table 2) .
By comparison, only partial regression of tumor growth has
been achieved via systemic administration of very high doses
of 11,2 (32, 33) . The potential advantages of localized secre-
tion of cytokines was suggested by the studies of Forni et
al . (34), who showed that local injection oflow doses ofsev-
eral cytokines including IIrl, IL2, or IFN-y, enhanced the
rejection of tumor cells admixed with tumor-specific T cells .
More recently, other investigators have demonstrated the anti-
tumor effect of cytokine gene transfer into tumor cells, using
the 1174 (35), IFN-y (36), and the IL2 genes (37) . Our studies
confirm the findings of Fearon et al . (37) that IL-2 secretion
by tumor cells can abrogate the tumorigenicity of those cells
and extend them by showing that it is a quantitative phe-
nomenon, correlating with the amount of IL2 secreted by
the tumor cells. In addition we show that (a) the immune
reaction induced prevents highly tumorigenic doses of co-
injected unmodified tumor cells from establishing a tumor ;
(b) that IL2 secretion by the tumor leads to a long-lasting
state ofT cell immunity as measured by persistence ofa specific
cytotoxic activity, not seen after injection ofunmodified tumor
cells ; and (c) in vitro data suggest that IL2 secretion into
the immediate surrounding of the tumor cells leads to amuch
more efficient lysis of the cytokine secreting CMS-5 cells .
Abrogation oftumorigenicity ofparentalCMS-5 cells ad-
mixed with IL2-producing counterparts suggests that the
inhibition was host mediated (Fig. 3) . Rejection of 8 x 105
tumor cells and significant inhibition of growth of 1.6 x
10 6 tumor cells admixed with IL2 producers attested to the
potency ofthe protective effect resulting from localized secre-
tion of IL2 in the vicinity of the emerging tumor. This was
confirmed in the experiment described in Table 3 which shows
that mice immunized with IL-2-producing tumor cells de-
veloped a specific and long-lasting immune response since
they are fully protected from a challenge with a highly tumori-
genic dose ofCMS-5 cells . The ability to induce protective
immunity using IL2-producing tumor cells compares favor-
ably with previous reports that haveshown that BALB/c mice
can be immunized against CMS-5 cells by two injections of
2.5 x 107 irradiated CMS-5 cells . The highest tumor chal-
lenge that could be rejected using this protocol was 75,000
CMS-5 cells (20) .
The emergence of a protective immune response against
the parental tumor cells correlated with the appearance of
tumor-specific cytotoxic T cells in spleens derived from mice
injected with IL2-producing CMS-5 cells, implicating this
effector arm ofthe immune system in their eradication (Fig .
4) . Persistence of a long-lasting immune response (Table 3)
and CTL activity in the spleens of mice injected with IL-
2-producing cells, but not in the spleens of mice injected
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tion of IL2 from the tumor cells led to the induction of a
long-lasting state of T cell immunity.
As shownin Fig . 5 (and Fig . 4, upper right), IL-2-secreting
CMS-5 cells, but notunmodifiedCMS-5 cells, were efficiently
and specifically lysedby spleen cells takenfrom mice injected
with unmodifiedCMS-5 cells at atime pointwhen the animals
were usuallyimmunosuppressed, raisingthe possibility that
(a) IL2 secretionby the tumor cells makes it possible to cir-
cumvent an existing state of suppression and (b) in the spleen
of an immunosuppressed tumorbearing animal, the suppressor
cells coexist with primed CTL. Theseresults can be also in-
terpreted to suggest that aweak anti-tumor immune response
induces T cell anergy that is overcome by IL2 .
Several observations described above rule out the possibility
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